Topic
PFA-100
About: PFA-100 is a research topic. Over the lifetime, 307 publications have been published within this topic receiving 11956 citations.
Papers published on a yearly basis
Papers
TL;DR: There was a trend toward increased age in patients with aspirin resistance or aspirin semiresponders, and there were no differences in aspirin sensitivity by race, diabetes, platelet count, renal disease, or liver disease.
Abstract: We determined the prevalence and clinical predictors of aspirin resistance by prospectively studying 325 patients with stable cardiovascular disease who were receiving aspirin (325 mg/day for ≥7 days) but no other antiplatelet agents. We also compared the detection of aspirin resistance with optical platelet aggregation, a widely accepted method, with a newer, more rapid method, the platelet function analyzer (PFA)-100, a whole blood test that measures platelet adhesion and aggregation ex vivo. Blood samples were analyzed in a blinded fashion for aspirin resistance by optical aggregation using adenosine diphosphate (ADP) and arachidonic acid, and by PFA-100 using collagen and/or epinephrine and collagen and/or ADP cartridges to measure aperture closure time. Aspirin resistance was defined as a mean aggregation of ≥70% with 10 μM ADP and a mean aggregation of ≥20% with 0.5 mg/ml arachidonic acid. Aspirin semiresponders were defined as meeting one, but not both of the above criteria. Aspirin resistance by PFA-100 was defined as having a normal collagen and/or epinephrine closure time (≤193 seconds). By optical aggregation, 5.5% of the patients were aspirin resistant and 23.8% were aspirin semiresponders. By PFA-100, 9.5% of patients were aspirin resistant. Of the 18 patients who were aspirin resistant by aggregation, 4 were also aspirin resistant by PFA-100. Patients who were either aspirin resistant or aspirin semiresponders were more likely to be women (34.4% vs 17.3%, p = 0.001) and less likely to be smokers (0% vs 8.3%, p = 0.004) compared with aspirin-sensitive patients. There was a trend toward increased age in patients with aspirin resistance or aspirin semiresponders (65.7 vs 61.3 years, p = 0.06). There were no differences in aspirin sensitivity by race, diabetes, platelet count, renal disease, or liver disease.
937 citations
TL;DR: It is found that impairment of von Willebrand factor, or inhibition of platelet receptors glycoprotein Ib or IIb/IIIa with monoclonal antibodies or peptides, resulted in abnormal closure times.
Abstract: A new in vitro system for the detection of platelet dysfunction, PFA-100™* has been developed It provides a quantitative measure of platelet function in anticoagulated whole blood The system comprises a microprocessor-controlled instrument and a disposable test cartridge containing a biologically active membrane The instrument aspirates a blood sample under constant vacuum from the sample reservoir through a capillary and a microscopic aperture cut into the membrane The membrane is coated with collagen and epinephrine or adenosine 5’-diphosphate The presence of these biochemical stimuli, and the high shear rates generated under the standardized flow conditions, result in platelet attachment, activation, and aggregation, slowly building a stable platelet plug at the aperture The time required to obtain full occlusion of the aperture is reported as the m“closure time” We have found that impairment of von Willebrand factor, or inhibition of platelet receptors glycoprotein Ib or IIblIIIa with monoclonal antibodies or peptides, resulted in abnormal closure times An antifibrinogen antibody, in contrast, failed to show any effect The test appears to be sensitive to platelet adherence and aggregation abnormalities The PFA-100™ system has potential applications in routine evaluation of platelet function in the clinical setting because of its accuracy, ease of operation, and rapid turnaround of results * Under evaluation
514 citations
TL;DR: The PFA‐100 closure time should be considered optional in the evaluation of platelet disorders and function, and its use in therapeutic monitoring of Platelet function is currently best restricted to research studies and prospective clinical trials.
412 citations
TL;DR: Since the last guidelines for BCSH platelet function testing were written in the late 1980s, many new tests have become available that are much simpler to use and are beginning to be utilized as point of care instruments.
381 citations
TL;DR: The PFA-100 demonstrates a high sensitivity, clearly superior to that of BT, for the screening of patients with von Willebrand disease, and is well adapted to routine testing, as it has the advantages of simplicity and ease of execution.
349 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 5 |
| 2016 | 5 |